Myelofibrosis

• Myelofibrosis is a rare chronic blood cancer characterized by the buildup of scar tissue in the bone marrow.
• Common myelofibrosis symptoms include fatigue, night sweats, weight loss, and an enlarged spleen.
• The primary myelofibrosis causes are often linked to genetic mutations, particularly in the JAK2, CALR, or MPL genes.
• Myelofibrosis treatment options range from watchful waiting to targeted therapies, stem cell transplantation, and supportive care.
• Living with myelofibrosis involves managing symptoms, adhering to treatment plans, and maintaining a focus on quality of life.

What is Myelofibrosis?

Myelofibrosis is a type of chronic myeloproliferative neoplasm (MPN), a group of blood cancers that originate in the bone marrow. In this condition, the bone marrow, which is responsible for producing all types of blood cells, develops scar tissue (fibrosis). This scarring progressively impairs the marrow’s ability to produce sufficient numbers of healthy red blood cells, white blood cells, and platelets. As a result, blood cell production often shifts to other organs, such as the spleen and liver, leading to their enlargement.

This rare disease affects approximately 1.5 out of every 100,000 people in the United States each year, according to the American Cancer Society, typically occurring in individuals over the age of 50. The progression of myelofibrosis can vary significantly among patients, from a slow, indolent course to a more aggressive form that may evolve into acute myeloid leukemia (AML).

Myelofibrosis Symptoms and Causes

The onset of myelofibrosis symptoms is often gradual, and in its early stages, the condition may not cause any noticeable signs. As the disease progresses and bone marrow function declines, symptoms typically emerge due to anemia, an enlarged spleen (splenomegaly), or other complications. Common symptoms include:

• Profound fatigue and weakness due to anemia
• Shortness of breath
• Night sweats
• Unexplained weight loss
• Fever
• Bone pain
• Easy bruising or bleeding
• A feeling of fullness or discomfort under the left ribs, caused by an enlarged spleen

The precise myelofibrosis causes are not fully understood, but the condition is primarily linked to acquired genetic mutations in the hematopoietic stem cells within the bone marrow. These mutations lead to the overproduction of abnormal cells, which then trigger the release of growth factors that cause scar tissue to form. The most common genetic mutations associated with myelofibrosis include:

In some cases, myelofibrosis can develop as a progression of other MPNs, such as polycythemia vera or essential thrombocythemia, which is referred to as secondary myelofibrosis. When it arises without a prior MPN, it is known as primary myelofibrosis.

Myelofibrosis Treatment Options and Living with the Condition

Myelofibrosis treatment options are tailored to the individual, considering their symptoms, risk factors, and overall health. The primary goals of treatment are to alleviate symptoms, improve blood counts, reduce spleen size, and potentially modify the disease course. For low-risk patients with minimal symptoms, a “watch and wait” approach may be adopted. For others, various interventions are available:

• JAK Inhibitors: Medications like ruxolitinib and fedratinib target the JAK-STAT pathway, which is often overactive in myelofibrosis due to mutations. These drugs can significantly reduce spleen size and alleviate constitutional symptoms such as fatigue, night sweats, and itching.
• Hematopoietic Stem Cell Transplantation (HSCT): This is the only potentially curative treatment for myelofibrosis. It involves replacing diseased bone marrow with healthy stem cells from a donor. HSCT is a high-risk procedure typically reserved for younger, higher-risk patients who are otherwise healthy enough to withstand the intensity of the treatment.
• Supportive Care: This includes treatments for anemia (e.g., red blood cell transfusions, erythropoiesis-stimulating agents), medications to manage an enlarged spleen (e.g., hydroxyurea, splenic radiation), and pain management.
• Clinical Trials: Participation in clinical trials offers access to new and investigational therapies that may provide additional benefits.

Living with myelofibrosis often involves a comprehensive approach to managing the chronic nature of the disease. Regular monitoring by a hematologist is crucial to track disease progression and adjust treatment as needed. Patients are encouraged to maintain a healthy lifestyle, including a balanced diet and moderate exercise, as tolerated, to help manage fatigue and improve overall well-being. Support groups and patient advocacy organizations can also provide valuable resources and emotional support for individuals and their families navigating the challenges of this condition.